ફેફસાનું કેન્સર (non-small cell)
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
ક્યાં જવું
આ ટ્રાયલ માટે ભારતમાં 6 હોસ્પિટલો દર્દીઓ લઈ રહી છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) …
સ્પોન્સર: Pfizer
NCT06758401 on ClinicalTrials.gov
રજિસ્ટ્રી પર છેલ્લે 25 Sep 2026 ના રોજ અપડેટ થયું · અમે 20 Oct 2026 ના રોજ વાંચ્યું